| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
50,880,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile HOOKIPA Pharma is a biopharmaceutical company developing a class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Co. is building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and antigens. Co.'s lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive cancers in a Phase 1/2 clinical trial. Co.'s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is a potential compound in a Phase 2 clinical trial for kidney transplant patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
47,000 |
47,000 |
| Total Buy Value |
$0 |
$0 |
$38,445 |
$38,445 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
7 |
7 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Christine D. |
Chief Business OfficerOfficer |
• – – |
2021-03-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,500 |
|
- |
|
| Matushansky Igor |
Chief Medical Officer |
• – – |
2020-12-17 |
4 |
S |
$11.70 |
$328,343 |
D/D |
(27,979) |
77,403 |
|
- |
|
| Matushansky Igor |
Chief Medical Officer |
• – – |
2020-12-17 |
4 |
OE |
$0.10 |
$4,899 |
D/D |
48,988 |
93,881 |
|
- |
|
| Matushansky Igor |
Chief Medical Officer |
• – – |
2020-12-16 |
4 |
S |
$11.70 |
$4,446 |
D/D |
(380) |
56,394 |
|
- |
|
| Matushansky Igor |
Chief Medical Officer |
• – – |
2020-12-16 |
4 |
OE |
$0.10 |
$64 |
D/D |
640 |
56,774 |
|
- |
|
| Kelly Michael Aaron |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,754 |
5,754 |
|
- |
|
| Lengauer Christoph |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,603 |
4,603 |
|
- |
|
| Seghezzi Graziano |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,708 |
4,708 |
|
- |
|
| Van Deventer Sander |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,485 |
2,485 |
|
- |
|
| Oneill Julie |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,969 |
4,969 |
|
- |
|
| Van De Winkel Jan |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,153 |
9,153 |
|
- |
|
| Kaufman David Ross |
Director |
– • – |
2020-10-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,577 |
4,577 |
|
- |
|
| Sofinnova Partners Sas |
10% Owner |
– – • |
2020-10-02 |
4 |
AS |
$10.00 |
$3,000 |
D/D |
(300) |
3,906,194 |
|
- |
|
| Sofinnova Partners Sas |
10% Owner |
– – • |
2020-09-15 |
4 |
AS |
$12.45 |
$524,477 |
D/D |
(41,597) |
3,906,494 |
|
- |
|
| Kandera Reinhard |
Chief Financial Officer |
• • – |
2020-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,036 |
2,036 |
|
- |
|
| Necina Roman |
Chief Technology Officer |
• – – |
2020-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,984 |
1,984 |
|
- |
|
| Aldag Jorn |
Chief Executive Officer |
• • – |
2020-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,128 |
4,128 |
|
- |
|
| Orlinger Klaus |
EVP, Research |
• – – |
2020-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,216 |
1,216 |
|
- |
|
| Sofinnova Partners Sas |
10% Owner |
– – • |
2020-07-20 |
4 |
AS |
$11.94 |
$149,102 |
D/D |
(12,483) |
3,948,091 |
|
- |
|
| Matushansky Igor |
Chief Medical Officer |
• – – |
2020-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
56,134 |
|
- |
|
| Sofinnova Partners Sas |
10% Owner |
– – • |
2020-06-29 |
4 |
AS |
$11.78 |
$38,628 |
D/D |
(3,280) |
3,960,574 |
|
- |
|
| Matushansky Igor |
Chief Medical Officer |
• – – |
2020-01-29 |
4 |
S |
$12.73 |
$69,992 |
D/D |
(5,500) |
53,398 |
|
- |
|
| Lilja Anders |
Sr. VP, Technical Development |
• – – |
2020-01-23 |
4 |
S |
$12.17 |
$146,533 |
D/D |
(11,643) |
0 |
|
- |
|
| Lilja Anders |
Sr. VP, Technical Development |
• – – |
2020-01-23 |
4 |
OE |
$0.10 |
$1,164 |
D/D |
11,643 |
7,568 |
|
- |
|
| Orlinger Klaus |
Sr. VP, Research |
• – – |
2020-01-14 |
4 |
S |
$11.30 |
$96,053 |
D/D |
(8,500) |
0 |
|
- |
|
59 Records found
|
|
Page 2 of 3 |
|
|
